Prostate cancer is a heritable and clinically heterogeneous cancer. Both long non-coding RNAs (lncRNAs) and microRNAs (miRs) have been implicated in the pathogenesis and development of prostate cancer. Analysis of microarray data indicated that the lncRNA LINC01207 was differentially expressed in prostate cancer. In silico analysis predicted the interaction between LINC01207 and miR-1972 as well as the interaction between miR-1972 and the mRNAs LIM and SH3 protein 1 (LASP1). Thus, we explored the role of LINC01207 and miR-1972 in the growth and progression of prostate cancer. Quantitative real-time polymerase chain reaction revealed that LINC01207 and LASP1 were highly expressed in prostate cancer, while miR-1972 expression was lower. The interaction among LINC01207, miR-1972, and LASP1 was confirmed by RNA-fluorescence in situ hybridization, RNA immunoprecipitation, and dual luciferase reporter assay, which verified that LINC01207 could bind to miR-1972 and downregulate miR-1972, and miR-1972 targeted LASP1 and negatively regulated its expression. Both in vitro and in vivo experiments found that silencing LINC01207 inhibited cell proliferation, migration, invasion and tumor formation and enhanced apoptosis in prostate cancer cells, suggesting that LINC01207 functioned as a tumor promoter in prostate cancer and that it may represent a novel therapeutic target.

中文翻译：

---

长链非编码 RNA LINC01207 通过下调 microRNA ‐1972 和上调 LIM 和 SH3 蛋白 1 促进前列腺癌进展

前列腺癌是一种具有遗传性和临床异质性的癌症。长链非编码 RNA (lncRNAs) 和 microRNAs (miRs) 都与前列腺癌的发病机制和发展有关。微阵列数据分析表明 lncRNA LINC01207 在前列腺癌中差异表达。计算机分析预测了 LINC01207 和 miR-1972 之间的相互作用以及 miR-1972 与 mRNA LIM 和 SH3 蛋白 1 (LASP1) 之间的相互作用。因此，我们探索了 LINC01207 和 miR-1972 在前列腺癌生长和进展中的作用。定量实时聚合酶链反应显示 LINC01207 和 LASP1 在前列腺癌中高表达，而 miR-1972 表达较低。通过 RNA 荧光原位杂交证实了 LINC01207、miR-1972 和 LASP1 之间的相互作用，RNA免疫沉淀和双荧光素酶报告基因检测，证实LINC01207可以与miR-1972结合并下调miR-1972，而miR-1972靶向LASP1并负调节其表达。体外和体内实验均发现，沉默LINC01207可抑制前列腺癌细胞的增殖、迁移、侵袭和肿瘤形成，并增强细胞凋亡，表明LINC01207在前列腺癌中起促癌作用，可能代表了一种新的治疗靶点。